266 related articles for article (PubMed ID: 12917817)
1. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Rosell R; Crino L; Danenberg K; Scagliotti G; Bepler G; Taron M; Alberola V; Provencio M; Camps C; De Marinis F; Sanchez JJ; Peñas R
Semin Oncol; 2003 Aug; 30(4 Suppl 10):19-25. PubMed ID: 12917817
[TBL] [Abstract][Full Text] [Related]
2. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
3. Genetic testing for chemotherapy in non-small cell lung cancer.
Rosell R; Taron M; Alberola V; Massuti B; Felip E
Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
[TBL] [Abstract][Full Text] [Related]
4. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
[TBL] [Abstract][Full Text] [Related]
5. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
6. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
7. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
9. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
de las Peñas R; Sanchez-Ronco M; Alberola V; Taron M; Camps C; Garcia-Carbonero R; Massuti B; Queralt C; Botia M; Garcia-Gomez R; Isla D; Cobo M; Santarpia M; Cecere F; Mendez P; Sanchez JJ; Rosell R;
Ann Oncol; 2006 Apr; 17(4):668-75. PubMed ID: 16407418
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
13. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
15. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
17. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics and gemcitabine.
Rosell R; Cobo M; Isla D; Camps C; Massuti B
Ann Oncol; 2006 May; 17 Suppl 5():v13-16. PubMed ID: 16807441
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Qiu ZQ; Zhao K
Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]